{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T22:43:10Z","timestamp":1791499390689,"version":"4.3.4"},"reference-count":35,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2018,3,2]],"date-time":"2018-03-02T00:00:00Z","timestamp":1519948800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P30 CA008748"],"award-info":[{"award-number":["P30 CA008748"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["K08 CA184038"],"award-info":[{"award-number":["K08 CA184038"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,8,16]]},"DOI":"10.1093\/cid\/ciy175","type":"journal-article","created":{"date-parts":[[2018,2,28]],"date-time":"2018-02-28T15:10:54Z","timestamp":1519830654000},"page":"687-692","source":"Crossref","is-referenced-by-count":257,"title":["Serious Infections in Patients Receiving Ibrutinib for Treatment of Lymphoid Cancer"],"prefix":"10.1093","volume":"67","author":[{"given":"Tilly","family":"Varughese","sequence":"first","affiliation":[{"name":"Infectious Diseases Service, Memorial Sloan Kettering Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Taur","sequence":"additional","affiliation":[{"name":"Infectious Diseases Service, Memorial Sloan Kettering Cancer Center"},{"name":"Department of Medicine, Weill Cornell Medical College"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nina","family":"Cohen","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Memorial Sloan Kettering Cancer Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M Lia","family":"Palomba","sequence":"additional","affiliation":[{"name":"Department of Medicine, Weill Cornell Medical College"},{"name":"Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan K","family":"Seo","sequence":"additional","affiliation":[{"name":"Infectious Diseases Service, Memorial Sloan Kettering Cancer Center"},{"name":"Department of Medicine, Weill Cornell Medical College"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias M","family":"Hohl","sequence":"additional","affiliation":[{"name":"Infectious Diseases Service, Memorial Sloan Kettering Cancer Center"},{"name":"Department of Medicine, Weill Cornell Medical College"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gil","family":"Redelman-Sidi","sequence":"additional","affiliation":[{"name":"Infectious Diseases Service, Memorial Sloan Kettering Cancer Center"},{"name":"Department of Medicine, Weill Cornell Medical College"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2018,4,27]]},"reference":[{"key":"key\n\t\t\t\t20180816010349_CIT0001","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1200\/JCO.2012.42.7906","article-title":"Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed\/refractory B-cell malignancies","volume":"31","author":"Advani","year":"2013","journal-title":"J Clin Oncol"},{"key":"key\n\t\t\t\t20180816010349_CIT0002","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/S1470-2045(13)70513-8","article-title":"Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b\/2 trial","volume":"15","author":"O\u2019Brien","year":"2014","journal-title":"Lancet Oncol"},{"key":"key\n\t\t\t\t20180816010349_CIT0003","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1182\/blood-2014-10-606038","article-title":"Three-year follow-up of treatment-na\u00efve and previously treated patients with CLL and SLL receiving single-agent ibrutinib","volume":"125","author":"Byrd","year":"2015","journal-title":"Blood"},{"key":"key\n\t\t\t\t20180816010349_CIT0004","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1056\/NEJMoa1215637","article-title":"Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia","volume":"369","author":"Byrd","year":"2013","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20180816010349_CIT0005","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1056\/NEJMoa1501548","article-title":"Ibrutinib in previously treated Waldenstr\u00f6m\u2019s macroglobulinemia","volume":"372","author":"Treon","year":"2015","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20180816010349_CIT0006","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1056\/NEJMoa1306220","article-title":"Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma","volume":"369","author":"Wang","year":"2013","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20180816010349_CIT0007","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1016\/S1470-2045(14)70311-0","article-title":"Combination of ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for treatment-naive patients with CD20-positive B-cell non-Hodgkin lymphoma: a non-randomised, phase 1b study","volume":"15","author":"Younes","year":"2014","journal-title":"Lancet Oncol"},{"key":"key\n\t\t\t\t20180816010349_CIT0008","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1016\/S1470-2045(14)70335-3","article-title":"Safety and activity of ibrutinib plus rituximab for patients with high-risk chronic lymphocytic leukaemia: a single-arm, phase 2 study","volume":"15","author":"Burger","year":"2014","journal-title":"Lancet Oncol"},{"key":"key\n\t\t\t\t20180816010349_CIT0009","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1111\/j.1600-065X.2008.00741.x","article-title":"Bruton\u2019s tyrosine kinase (Btk): function, regulation, and transformation with special emphasis on the PH domain","volume":"228","author":"Mohamed","year":"2009","journal-title":"Immunol Rev"},{"key":"key\n\t\t\t\t20180816010349_CIT0010","doi-asserted-by":"crossref","first-page":"288","DOI":"10.4049\/jimmunol.181.1.288","article-title":"Dual functions of Bruton\u2019s tyrosine kinase and Tec kinase during Fc\u03b3 receptor-induced signaling and phagocytosis","volume":"181","author":"Jongstra-Bilen","year":"2008","journal-title":"J Immunol"},{"key":"key\n\t\t\t\t20180816010349_CIT0011","doi-asserted-by":"crossref","first-page":"e1003446","DOI":"10.1371\/journal.ppat.1003446","article-title":"Bruton\u2019s tyrosine kinase (BTK) and Vav1 contribute to dectin1-dependent phagocytosis of Candida albicans in macrophages","volume":"9","author":"Strijbis","year":"2013","journal-title":"PLoS Pathog"},{"key":"key\n\t\t\t\t20180816010349_CIT0012","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/j.ccell.2017.04.012","article-title":"Inhibition of B cell receptor signaling by ibrutinib in primary CNS lymphoma","volume":"31","author":"Lionakis","year":"2017","journal-title":"Cancer Cell"},{"key":"key\n\t\t\t\t20180816010349_CIT0013","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1038\/361226a0","article-title":"The gene involved in X-linked agammaglobulinaemia is a member of the src family of protein-tyrosine kinases","volume":"361","author":"Vetrie","year":"1993","journal-title":"Nature"},{"key":"key\n\t\t\t\t20180816010349_CIT0014","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/0092-8674(93)90667-F","article-title":"Deficient expression of a B cell cytoplasmic tyrosine kinase in human X-linked agammaglobulinemia","volume":"72","author":"Tsukada","year":"1993","journal-title":"Cell"},{"key":"key\n\t\t\t\t20180816010349_CIT0015","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1126\/science.8332900","article-title":"Colocalization of X-linked agammaglobulinemia and X-linked immunodeficiency genes","volume":"261","author":"Thomas","year":"1993","journal-title":"Science"},{"key":"key\n\t\t\t\t20180816010349_CIT0016","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1097\/00005792-199611000-00001","article-title":"X-linked agammaglobulinemia: a clinical and molecular analysis","volume":"75","author":"Ochs","year":"1996","journal-title":"Medicine (Baltimore)"},{"key":"key\n\t\t\t\t20180816010349_CIT0017","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1007\/s00277-017-2944-7","article-title":"Disseminated fusarium infection after ibrutinib therapy in chronic lymphocytic leukaemia","volume":"96","author":"Chan","year":"2017","journal-title":"Ann Hematol"},{"key":"key\n\t\t\t\t20180816010349_CIT0018","first-page":"27","article-title":"Invasive aspergillosis related to ibrutinib therapy for chronic lymphocytic leukemia","volume":"21","author":"Arthurs","year":"2017","journal-title":"Respir Med Case Rep"},{"key":"key\n\t\t\t\t20180816010349_CIT0019","first-page":"4642831","article-title":"Disseminated cryptococcal disease in a patient with chronic lymphocytic leukemia on ibrutinib","volume":"2016","author":"Okamoto","year":"2016","journal-title":"Case Rep Infect Dis"},{"key":"key\n\t\t\t\t20180816010349_CIT0020","doi-asserted-by":"crossref","first-page":"E646","DOI":"10.1002\/ajh.24890","article-title":"Ibrutinib-associated Pneumocystis jirovecii pneumonia","volume":"92","author":"Lee","year":"2017","journal-title":"Am J Hematol"},{"key":"key\n\t\t\t\t20180816010349_CIT0021","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1182\/blood-2016-06-722991","article-title":"Atypical Pneumocystis jirovecii pneumonia in previously untreated patients with CLL on single-agent ibrutinib","volume":"128","author":"Ahn","year":"2016","journal-title":"Blood"},{"key":"key\n\t\t\t\t20180816010349_CIT0022","first-page":"1593","article-title":"Ibrutinib for chronic lymphocytic leukemia","volume":"374","author":"Ruchlemer","year":"2016","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20180816010349_CIT0023","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1093\/cid\/cix687","article-title":"Call for action: invasive fungal infections associated with ibrutinib and other small molecule kinase inhibitors targeting immune signaling pathways","volume":"66","author":"Chamilos","year":"2018","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20180816010349_CIT0024","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2017-11-818286","article-title":"Early-onset invasive aspergillosis and other fungal infections in patients treated with ibrutinib","author":"Ghez","year":"2018","journal-title":"Blood"},{"issue":"12","key":"key\n\t\t\t\t20180816010349_CIT0025","doi-asserted-by":"crossref","first-page":"2981","DOI":"10.1080\/10428194.2017.1320710","article-title":"Fungal infections in patients treated with ibrutinib: two unusual cases of invasive aspergillosis and cryptococcal meningoencephalitis","volume":"58","author":"Baron","year":"2017","journal-title":"Leuk Lymphoma"},{"key":"key\n\t\t\t\t20180816010349_CIT0026","doi-asserted-by":"crossref","first-page":"ofw261","DOI":"10.1093\/ofid\/ofw261","article-title":"Disseminated cryptococcosis with brain involvement in patients with chronic lymphoid malignancies on ibrutinib","volume":"4","author":"Messina","year":"2017","journal-title":"Open Forum Infect Dis"},{"key":"key\n\t\t\t\t20180816010349_CIT0027","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1086\/588660","article-title":"Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer\/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC\/MSG) Consensus Group","volume":"46","author":"De Pauw","year":"2008","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20180816010349_CIT0028","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1002\/hon.2343","article-title":"Epidemiology and risk factors of invasive fungal infections in a large cohort of patients with chronic lymphocytic leukemia","volume":"35","author":"Visentin","year":"2017","journal-title":"Hematol Oncol"},{"key":"key\n\t\t\t\t20180816010349_CIT0029","doi-asserted-by":"crossref","first-page":"774","DOI":"10.3390\/ijms13010774","article-title":"Invasive fungal infections in patients with hematologic malignancies (AURORA Project): lights and shadows during 18-months surveillance","volume":"13","author":"Montagna","year":"2012","journal-title":"Int J Mol Sci"},{"key":"key\n\t\t\t\t20180816010349_CIT0030","article-title":"X-linked agammaglobulinemia","volume-title":"GeneReviews","author":"Smith","year":"1993\u20132018"},{"key":"key\n\t\t\t\t20180816010349_CIT0031","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1007\/s40266-017-0468-4","article-title":"Current status of Bruton\u2019s tyrosine kinase inhibitor development and use in B-cell malignancies","volume":"34","author":"Aw","year":"2017","journal-title":"Drugs Aging"},{"key":"key\n\t\t\t\t20180816010349_CIT0032","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1002\/cpt.85","article-title":"Targeting Bruton\u2019s tyrosine kinase with ibrutinib in B-cell malignancies","volume":"97","author":"Wang","year":"2015","journal-title":"Clin Pharmacol Ther"},{"key":"key\n\t\t\t\t20180816010349_CIT0033","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1182\/blood-2016-10-747345","article-title":"Targeting Bruton tyrosine kinase with ibrutinib in relapsed\/refractory marginal zone lymphoma","volume":"129","author":"Noy","year":"2017","journal-title":"Blood"},{"key":"key\n\t\t\t\t20180816010349_CIT0034","doi-asserted-by":"crossref","first-page":"2243","DOI":"10.1182\/blood-2017-07-793786","article-title":"Ibrutinib for chronic graft-versus-host disease after failure of prior therapy","volume":"130","author":"Miklos","year":"2017","journal-title":"Blood"},{"key":"key\n\t\t\t\t20180816010349_CIT0035","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.ctrv.2017.06.001","article-title":"Bruton\u2019s tyrosine kinase (BTK) as a promising target in solid tumors","volume":"58","author":"Molina-Cerrillo","year":"2017","journal-title":"Cancer Treat Rev"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/cid\/article-pdf\/67\/5\/687\/25496746\/ciy175.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,28]],"date-time":"2020-10-28T17:16:02Z","timestamp":1603905362000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article\/67\/5\/687\/4917700"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4,27]]},"references-count":35,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2018,4,27]]},"published-print":{"date-parts":[[2018,8,16]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/ciy175","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.732806284.793562614","asserted-by":"object"}]},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"value":"1058-4838","type":"print"},{"value":"1537-6591","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2018,9,1]]},"published":{"date-parts":[[2018,4,27]]}}}